Loading…

Surface Plasmon Resonance Assay for Identification of Small Molecules Capable of Inhibiting Aβ Aggregation

Toxic aggregates of amyloid-beta (Aβ) have importance in the pathology of Alzheimer’s disease, and inhibition of aggregate formation is considered to be a promising strategy for drug development. Here, we report a simple and rapid surface plasmon resonance (SPR) assay method that can identify potent...

Full description

Saved in:
Bibliographic Details
Published in:ACS applied materials & interfaces 2021-06, Vol.13 (24), p.27845-27855
Main Authors: Lee, Jeeyeon, Lee, Kwan, Lim, Chwee Teck
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Toxic aggregates of amyloid-beta (Aβ) have importance in the pathology of Alzheimer’s disease, and inhibition of aggregate formation is considered to be a promising strategy for drug development. Here, we report a simple and rapid surface plasmon resonance (SPR) assay method that can identify potential Aβ aggregation inhibitors. Our assay is based on the SPR shifting of the Aβ-gold nanoparticle (Aβ-GNP) aggregates by size under the influence of an Aβ aggregation inhibitor. This user-friendly assay features a short assay time with a low reagent consumption that can be easily adapted as a high-throughput screen. We demonstrated that an effective Aβ aggregation inhibitor induces the blue-shifted SPR peaks of the Aβ-GNP aggregates by hindering the formation of long fibrillar aggregates. Moreover, the blue shifting was correlated to the efficacy and concentrations of an Aβ aggregation inhibitor. Overall, our findings suggest that our simple SPR assay can be a powerful tool to screen small molecules targeting Aβ aggregation.
ISSN:1944-8244
1944-8252
DOI:10.1021/acsami.1c04833